DUCELL/SOL
Capricor said the FDA is willing to review new data for deramiocel, its experimental Duchenne muscular dystrophy therapy, after an advisory panel previously rejected its effectiveness evidence. The sudden regulatory turn made the experimental cell therapy a closely watched health story.
Score | 32 |
|---|---|
24h Vol | $13.9K |
Liquidity | $0 |
Holders | 11 |
Audits | |
Age | 3 hours |
FDV | $0.16 |
Market Cap | $0.16 |
| Addresses | |
|---|---|
| Pool | |
| DUCELL | |
| SOL |  |
DUCELL to SOL Converter
Score | 32 |
|---|---|
24h Vol | $13.9K |
Liquidity | $0 |
Holders | 11 |
Audits | |
Age | 3 hours |
FDV | $0.16 |
Market Cap | $0.16 |
About DUCHENNE CELL (DUCELL)
Capricor said the FDA is willing to review new data for deramiocel, its experimental Duchenne muscular dystrophy therapy, after an advisory panel previously rejected its effectiveness evidence. The sudden regulatory turn made the experimental cell therapy a closely watched health story.
Update Token InfoDUCELL/SOL Price Stats
The current price of DUCELL (DUCELL/SOL) on PumpSwap is $0.0002594, the price is up -97.12% in the last 24 hours. Its 24-hour trading volume is reported to be at $13,888.80 with a total of 49 transactions. DUCELL/SOL contract address is GK56WdUoQCbF9wBJQGQGchW7FbMJPS3Yv1wea9kQdXh, with a Fully Diluted Valuation (FDV) of $0.1642 and a liquidity pool of $0.00006.
